CC
ROIV icon

Centiva Capital’s Roivant Sciences ROIV Stock Holding History

Centiva Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,596
Closed -$210K – 2166
2026
Q1 		$210K Buy
+7,596
New +$195K ﹤0.01% 1253
2024
Q3 		– Sell
-30,034
Closed -$317K – 2533
2024
Q2 		$317K Sell
30,034
-129,763
-81% -$1.42M 0.01% 1423
2024
Q1 		$1.68M Buy
159,797
+154,538
+2,939% +$1.67M 0.04% 402
2023
Q4 		$59.1K Sell
5,259
-44,715
-89% -$436K ﹤0.01% 1635
2023
Q3 		$584K Buy
+49,974
New +$565K 0.01% 883
2022
Q4 		– Sell
-155,624
Closed -$501K – 1593
2022
Q3 		$501K Sell
155,624
-349,566
-69% -$1.35M 0.01% 877
2022
Q2 		$2.06M Buy
505,190
+136,694
+37% +$543K 0.05% 346
2022
Q1 		$1.82M Buy
+368,496
New +$2.43M 0.03% 466

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Centiva Capital's ROIV Position: Q2 2026 in Review

Centiva Capital sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 7,596 shares — an estimated $210K sold.

Centiva Capital first reported a position in ROIV in Q1 2022 and held it in 8 quarters. The position peaked at $2.06M in Q2 2022. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Centiva Capital reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 7,596 Roivant Sciences shares in Q2 2026, an estimated $210K.
  • Centiva Capital first reported a position in Roivant Sciences in Q1 2022 and held it in 8 quarters.
  • Centiva Capital's Roivant Sciences position peaked at $2.06M in Q2 2022.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.